Barclays Starts Coherus Biosciences (CHRS) at Overweight
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $2.02 --0%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
Barclays initiated coverage on Coherus Biosciences (NASDAQ: CHRS) with an Overweight rating and a price target of $46.00.
For an analyst ratings summary and ratings history on Coherus Biosciences click here. For more ratings news on Coherus Biosciences click here.
Shares of Coherus Biosciences closed at $27.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Berenberg Starts Lloyds TSB Group (LYG) at Hold, 'shares are fairly valued'
- Marex Group plc Announces Pricing of Initial Public Offering
- Barclays Q1 profit falls 12% as trading slump hits
Create E-mail Alert Related Categories
New CoverageRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
